Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

Cell Death and Disease

Volumn 1, Issue 8, 2010, Pages

  Schneider, B ^a   Munkel S ^a   Krippner Heidenreich, A ^b   Grunwald, I ^c   Wels, W S ^d   Wajant, H ^e   Pfizenmaier, K ^a   Gerspach, J ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c FRAUNHOFER INSTITUTE FOR MANUFACTURING TECHNOLOGY AND ADVANCED MATERIALS IFAM   (Germany)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Apoptosis; ErbB2; scFv TRAIL fusion proteins; Single chain TRAIL; Tumor targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY SINGLE POLYPEPTIDE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; SINGLE POLYPEPTIDE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPITOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; COLON CARCINOMA; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; GENE FUSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; BLOOD; CELL DEATH; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; HALF LIFE TIME; HUMAN; NUDE MOUSE; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; EPITOPES; HALF-LIFE; HUMANS; MICE; MICE, NUDE; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959921520     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.45     Document Type: Article

References (47)

1. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77:311-319. (Pubitemid 351206593)
2. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006;6:6.
3. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9:1002-1011.
4. Gerspach J, Wajant H, Pfizenmaier K. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 2009;49:241-273.
5. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009;14:607-623.
6. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006;130:141-165.
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163. (Pubitemid 29068521)
9. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002;62:5800-5806. (Pubitemid 35204738)
10. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22.
11. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-1990. (Pubitemid 351872316)
12. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009;647:195-206.
13. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001;20:4101-4106. (Pubitemid 32681615)
14. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, DeForge L et al. Receptorselective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosisinducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-2212.
15. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-798.
16. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-935. (Pubitemid 47282789)
17. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217. (Pubitemid 38263839)
18. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.
19. Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-184.
20. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kuhnle M, Gerspach J, Sterns T et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008;180:8176-8183.
21. Wels W, Harwerth IM, Zwickl M, Hardman N, Groner B, Hynes NE. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology (NY) 1992;10:1128-1132.
22. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 1989;39:167-173. (Pubitemid 19062782)
23. Luciano F, Ricci JE, Herrant M, Bertolotto C, Mari B, Cousin JL et al. T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma. Leukemia 2002;16:700-707. (Pubitemid 34449753)
24. Guo F, Sigua C, Tao J, Bali P, George P, Li Y et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-2589. (Pubitemid 38523916)
25. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000;275:32208-32213.
26. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and-enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004;109:281-290. (Pubitemid 38240933)
27. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005;65:3380-3388. (Pubitemid 40524623)
28. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S et al. Apo2L/TRAIL pharmacokinetics in a phase Ia trial in advanced cancer and lymphoma. J Clin Oncol 2006;24:3047.
29. Herbst RS, Mendelson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006;24:3013.
30. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;290:G129-G136.
31. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003;22:3842-3852. (Pubitemid 36819657)
32. Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007;46:1498-1508. (Pubitemid 350155532)
33. Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS One 2009;4:e4623.
34. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005;54:1590-1596. (Pubitemid 41531777)
35. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 2008;105:10895-10900.
36. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-1136. (Pubitemid 41486394)
37. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007;14:2021-2034. (Pubitemid 350131152)
38. Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G et al. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 2006;84:785-797. (Pubitemid 44328069)
39. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-430. (Pubitemid 37328939)
40. Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-38. (Pubitemid 32905115)
41. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004;32:1230-1238. (Pubitemid 39410906)
42. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68:1140-1145. (Pubitemid 23356666)
43. Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE, Groner B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene 1995;159:73-80.
44. Stagg J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H et al. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 2008;105:16254-16259.
45. Wuest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 2002;21:4257-4265. (Pubitemid 34753832)
46. Harwerth IM, Wels W, Marte BM, Hynes NE. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 1992;267:15160-15167.
47. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-974. (Pubitemid 17012421)